SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 55.32+2.7%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (10408)2/12/2004 10:12:01 AM
From: Ian@SI  Read Replies (1) of 52153
 
... a "safety only" regime where new drugs could be sold once minimal safety had been demonstrated (no requirement that efficacy be demonstrated)

Ouch! I'm not sure that I'd want to put that much trust in any corporation. Looking at the Accutane label, the side effects include Organ damage, nerve damage, muscle damage, psychological disorders, ... Some side effects persist even after Accutane therapy is stopped. And this is to give someone the hope of getting rid of some pimples.

While I agree that something needs to happen to make it more efficient to get new drugs to market, I'd be reluctant to drop the "efficacy measure".

FWIW,
Ian
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News